Yang Zongguo, Zhuang Liping, Yu Yuan, Zhou Weili, Lu Yunfei, Xu Qingnian, Tang Bozong, Chen Xiaorong
Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Discov Med. 2015 Dec;20(112):349-56.
The relationship between members of APOBEC3 in tumor tissues and hepatocellular carcinoma prognosis was not well studied. We compared APOBEC3 expression between tumor and non-tumor tissues based on the expression profile GSE14520 from Gene Expression Omnibus (GEO), and correlated APOBEC3 in tumor tissues with outcomes of HCC patients. APOBEC3B, which was significantly up-regulated in HCC tumor tissues (P < 0.001), was negatively associated with HCC overall survival by Cox regression (HR = 1.005, 95% CI = 1.0-1.009, P = 0.033). However, no significant difference was found of APOBEC3B and HCC overall survival by Kaplan-Meier method. HCC patients with high APOBEC3F expression in tumor tissues more likely coexist with multinodular tumors than those with low APOBEC3F level (26.4% and 13.6%, respectively, P = 0.018). Cox univariate and multivariate regression analyses revealed that APOBEC3F overexpression in tumor tissues was negatively associated with HCC recurrence (HR = 1.132, 95% CI = 1.013-1.265, P = 0.028). Additionally, the higher the APOBEC3F expressed, the greater risk of poor recurrence-free survival for HCC patients (mean survival time high = 32.25 and low = 42.68 months, respectively; log rank P = 0.012) when grouped by lower quartile cut-off of 10.98.
Overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-HCC patients. The role of other APOBEC3 members in HCC development needed further research.
肿瘤组织中载脂蛋白B mRNA编辑酶催化多肽样3(APOBEC3)成员与肝细胞癌预后之间的关系尚未得到充分研究。我们基于基因表达综合数据库(GEO)中的表达谱GSE14520比较了肿瘤组织与非肿瘤组织中APOBEC3的表达,并将肿瘤组织中的APOBEC3与肝癌患者的预后相关联。APOBEC3B在肝癌肿瘤组织中显著上调(P < 0.001),通过Cox回归分析显示其与肝癌总生存期呈负相关(风险比[HR] = 1.005,95%置信区间[CI] = 1.0 - 1.009,P = 0.033)。然而,通过Kaplan - Meier法未发现APOBEC3B与肝癌总生存期存在显著差异。肿瘤组织中APOBEC3F高表达的肝癌患者比APOBEC3F低水平患者更易合并多结节肿瘤(分别为26.4%和13.6%,P = 0.018)。Cox单因素和多因素回归分析显示,肿瘤组织中APOBEC3F过表达与肝癌复发呈负相关(HR = 1.132,95% CI = 1.013 - 1.265,P = 0.028)。此外,当以10.98的下四分位数进行分组时,APOBEC3F表达越高,肝癌患者无复发生存不良风险越大(高表达组平均生存时间 = 32.25个月,低表达组平均生存时间 = 42.68个月;对数秩检验P = 0.012)。
肿瘤组织中APOBEC3F过表达可能预示乙肝相关肝癌患者无复发生存不良。其他APOBEC3成员在肝癌发生发展中的作用有待进一步研究。